Astellas Pharma Inc. has invested $50 million in Taysha Gene Therapies Inc. in exchange for 15% of the company and exclusive options to in-license Taysha’s lead gene therapy candidates, TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy.
Compounds acting as AMP-activated protein kinase (AMPK) activators and prostaglandin G/H synthase 2 (PTGS2; COX2) inhibitors have been reported by Nanjing Shupeng Lifescience to be useful for the treatment of pain and inflammatory disorders, among others.
Reduced expression of nuclear factor erythroid 2-related factor 2 (Nrf2) is observed in humans and animal models of Alzheimer’s disease (AD), with its activation being a promising therapeutic approach.
Gb Sciences Inc. has received promising preclinical results in an interim report from a study using its plant-based compounds in preclinical zebrafish models of stress at the National Research Council of Canada (NRC).
Enveric Biosciences Inc. has nominated EB-373 as the lead development candidate to emerge from its EVM201 program. EB-373 is under development for the treatment of anxiety disorders.
Synaptive Medical Inc. has introduced a free water correction feature to its Modus Plan software to restore tracts in areas surrounding brain lesions affected by edema and which interferes with automated mapping of the brain. Water from edema obscures retrieval of diffusion tensor imaging (DTI) data and tractography mapping used to evaluate white matter pathways in the brain.
RNA binding fox-1 homologue 1 (RBFOX1) is a splicing factor that regulates alternative splicing and modulates the expression of several genes involved in brain development, and it is among the top identified loci related to psychiatric disorders.
Researchers from Astellas Pharma Inc. presented preclinical data for the novel 5-HT5A receptor antagonist, ASP-5736, being developed for the treatment of fragile X syndrome (FXS).
Approval of a new depression drug, stellar phase III data for both a schizophrenia therapy and an Alzheimer’s disease candidate, as well as an accelerated approval filing for a Duchenne muscular dystrophy gene therapy, are all reasons that BioWorld’s Neurological Diseases Index climbed from a negative position throughout much of 2022 to its 11% above-water mark as of Oct. 20.
Standigm Inc. has identified new phenylaminopyrimidine leucine-rich repeat kinase 2 (LRRK2; Dardarin) (G2019S mutant) inhibitors reported to be useful for the treatment neurodegeneration, among other disorders.
RSS
